US-based BostonGene Corporation and Japanese firm NEC Corporation have announced a strategic global partnership agreement that will enable the companies to offer BostonGene Tumor Portrait^TM Tests in key international markets, including Japan as the first market outside of the US.

BostonGene’s innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient’s immune system and the effectiveness of all available approved and experimental treatments. BostonGene Tumor Portrait™ Tests, based on integrated genomic and transcriptomic analysis, propel precision medicine into daily clinical practice and support physicians in actualizing personalized therapy for cancer patients.

Moreover, in NEC’s ongoing personalized neoantigen clinical trial that utilizes its AI-driven neoantigen prediction technology, NEC and BostonGene are collaborating to provide molecular characterization of patient tumors. Going forward, the two companies will jointly develop the market for BostonGene Tumor Portrait™ Tests globally.

In Japan, the companies aim to utilize NEC's healthcare and life science network in order to provide Tumor Portrait™ Tests to hospitals throughout the country.